HIMS Q2 2026 - Post-Call Earnings Update

Event: Quartr Q2 2026 event Retrieved: 2026-08-11T12:00:00Z Comparison mode: maximal Scorecard contract: v1

Consensus scorecard

• Consensus scorecard, bulleted equivalent (carried forward unchanged from the preliminary report for this event):
  • Revenue / total revenue: Quartr actual $753.214m against API Ninjas consensus $698.900m - Beat +$54.315m, +7.8%.
  • EPS / GAAP diluted: Quartr actual $(0.37) against API Ninjas consensus $(0.049) - Miss −$0.321, −655.1%.

Management and Q&A

• THE LEGAL CONTINGENCY IS THE FTC, AND IT IS CONTESTED, NOT SETTLED. This is the single largest resolution of a preliminary open question. The preliminary flagged $47.5m of legal contingencies in the quarter, and $62.5m over six months, that the release did not describe, size by matter, or characterize as final. On the call the CFO named it: the accrual relates to litigation with the Federal Trade Commission. He stated that after nearly three years of cooperation throughout the FTC's investigation and several months of good-faith settlement negotiations, the FTC filed a complaint on July 29, and that "we were not prepared to accept the terms we do not believe reflect the facts or the law." He added that the company is confident in its position and intends to defend it vigorously. The accrual is therefore a contingency booked against active, contested litigation rather than a concluded settlement, so the preliminary's question of whether further charges follow remains genuinely open and now has a named cause.
• The $81m of non-recurring costs was itemized by category for the first time: acquisition and transaction costs primarily related to the Eucalyptus closing, restructuring costs following the weight-loss strategic pivot earlier this year, and the FTC legal contingency accruals. The CFO said these primarily hit G&A, operations and support, and that the rest of his commentary excluded them.
• EUCALYPTUS CONTRIBUTION QUANTIFIED. The preliminary could not separate acquired from organic international revenue. The CFO disclosed that Eucalyptus contributed approximately $40m of revenue in the second quarter against total international revenue of $131m, and that the pre-existing international business grew 13% quarter over quarter organically. Asked directly by Eric Percher (Nephron Research) whether subscriber growth included Eucalyptus, the CFO confirmed Eucalyptus is in both top and bottom line for the quarter but said the material driver behind the raised guide is accelerating domestic revenue, not the acquisition.
• Domestic detail the release did not break out: US operations generated $622m of revenue with growth accelerating to 16% year over year. The CFO attributed the re-acceleration to the March pivot to expand the assortment of branded weight-loss products, which added enough subscribers to offset the revenue-recognition headwind from moving branded weight loss to a monthly cadence.
• GROSS MARGIN IS GUIDED STRUCTURALLY LOWER, WHICH THE RELEASE DID NOT SAY. The CFO described the 64% gross margin as down roughly six points sequentially on an adjusted basis and attributed it to deliberate strategic action to scale branded weight loss and international. He then made a forward statement absent from the release: "As branded weight loss products and international revenue become a larger portion of the business, we expect gross margins will remain below the levels we have historically achieved," and confirmed the same dynamics persist through the second half. He did not quantify the split between the Eucalyptus consolidation, the US weight-loss shift, and underlying pricing, so that part of the preliminary's question is unresolved.
• Offsetting cost lines were quantified: marketing improved five points year over year and two points sequentially to 34% of revenue; operations and support delivered three points of sequential leverage; and the CFO said technology and G&A showed modest sequential leverage, which he called an early signal that the investment can be accretive.
• CASH FLOW AND FINANCING. Second-quarter operating cash flow was negative $36m and free cash flow negative $68m, which the CFO attributed to working capital demands from the branded weight-loss offering; trailing twelve-month operating cash flow was over $260m. Two financings were completed since the first quarter: a $400m receivables facility to convert short-dated branded weight-loss receivables into cash, and a convertible debt offering of over $400m. After the approximately $225m upfront Eucalyptus payment, the company ended the quarter with more than $840m of cash and short-term investments, with $225m remaining on the share repurchase authorization. Management expects to resume free cash flow generation in the second half.
• AI, with metrics attached. The Hers weight-loss AI care experience began a phased rollout in early July. Customers in it send three times as many messages, AI answers 80% of their questions, and non-clinical tasks handled by support teams fell by nearly 50%. Management says it has already meaningfully reduced reliance on third-party agentic AI customer support vendors and expects to roll off them completely. The CFO put the payback on AI investment at 12 to 18 months. The company is opening an AI R&D lab in Menlo Park and hiring AI talent.
• PRICE CUTS ARE BEING SIGNALLED. The CFO said that if AI efficiency gains continue, "our expectation is that we will unlock more value for our weight loss subscribers by the end of the year in the form of lower prices and/or additional tools," explicitly comparing it to the sexual health and hair loss playbook where scale funded price reductions. He also stated a capital allocation standard of a one year or less breakeven period for incremental investment.
• Peptides: management is waiting for full and final FDA rulemaking, not merely the start of proposed rulemaking, before selling the six peptides recommended at the July PCAC hearing. Asked by Ryan MacDonald (Needham) to clarify exactly that distinction, the CEO said "our operating model today is that we are waiting on full and final rulemaking from the FDA." In the meantime BPC-157 is going onto stability and validation testing at the Menlo Park API facility, and already-allowed peptides including sermorelin, glutathione and NAD+ are planned before year end.
• Testosterone is the standout new specialty: scaling faster than any other outside weight loss only three quarters after launch, expected to become the sixth US specialty at a $100m annual run rate, with injectable and oral TRT planned before year end. Dr. Anant Vinjamoori joined as Chief Medical Officer of Hims covering hormonal health, longevity medicine and peptide therapy.
• Scale markers stated on the call: nearly 3 million global subscribers after adding roughly 300,000 in the quarter; five US specialties above a $100m annual run rate; the UK, Australia and Germany each above $100m annualized with Canada on track; and Hers on track for north of $1bn of revenue this year.
• Novo Nordisk: management described the relationship as strong in the US and extending internationally through Eucalyptus relationships, said the Wegovy pill launch has been "staggering" and that Hims is one of the largest players helping consumers access it, and cited tens of thousands of waitlist signups in Germany and the UK within days. Asked by Maria Ripps (Canaccord) how branded-cohort retention compares, the CFO said retention is "aligning with our expectations" and that a large part of the Q2 beat came from the weight category being stronger than expected, which is what gave management conviction to raise guidance.
• The CEO floated two offerings not in the release: a membership offering "coming out in the coming year or two" and a freemium tier, both framed as making concierge-style care, which he priced at $50,000 to $150,000 annually today, universally accessible.

Guidance and KPI clarification

• Guidance, bulleted equivalent: third-quarter revenue is guided to $880m to $900m, an increase of approximately 47% to 50% year over year, with adjusted EBITDA of $75m to $95m, a 10% margin at the midpoint of both ranges. Full-year 2026 revenue guidance was raised to $3.1bn to $3.3bn, an increase of 32% to 41%, with full-year adjusted EBITDA of $275m to $325m, a 9% margin at the midpoint of both ranges. International revenue is guided to at least $600m for 2026 and is expected to operate at or near breakeven on an adjusted EBITDA basis while the company prioritizes scale. The 2030 ambitions of at least $6.5bn of revenue and $1.3bn of adjusted EBITDA were reaffirmed. Management stated an expected payback of 12 to 18 months on AI investment and a capital allocation standard of a one year or less breakeven period.
• THE FULL-YEAR ADJUSTED EBITDA REVISION, WHICH THE PRELIMINARY COULD NOT DIRECTION. The preliminary flagged that the release updated full-year adjusted EBITDA without restating the prior range, so the direction of the revision was undeterminable. The call does not restate the prior range either, but Mark Mahaney of Evercore framed his question around "the EBITDA kind of shading down or cut in the full year guidance" and asked whether Eucalyptus dilution was part of it. Management did not contest that characterization. The CFO answered by pointing to expected acceleration in both US revenue and EBITDA in the second half, driven by cohort stacking from the switch to a monthly branded cadence, improving retention from the AI tools, and reinvestment of AI efficiency savings into weight-loss pricing and international expansion. On that exchange the full-year adjusted EBITDA guide is best read as having been revised down, but the reduction is inferred from an analyst's unchallenged framing rather than from a figure either the release or the call stated.
• The second-half adjusted EBITDA step-up the preliminary flagged is now explained, though not bridged numerically. Against $104.603m of first-half adjusted EBITDA, the $275m-$325m full-year guide implies $170.4m-$220.4m in the second half. The CFO attributes the gap to the compounding effect of weight-loss cohorts acquired through the first half, continued operating expense leverage, and re-accelerating US revenue growth. He also said guidance is deliberately built to preserve flexibility to invest further if opportunities materialize, which means the range is as much a spending decision as a forecast.
• Glen Santangelo of Barclays put the implied fourth-quarter adjusted EBITDA margin at approximately 12% at the midpoint and asked whether that is a fair jumping-off point for 2027 given the 20% margin implied by the 2030 target. Management did not dispute the 12% arithmetic but declined to speak to 2027, redirecting to a philosophy of prioritizing free cash flow generation and aggregate adjusted EBITDA dollars over the next several quarters.
• Adjusted EBITDA of $60m in the quarter was described as an 8% margin and a one-point sequential improvement, with operating leverage more than offsetting the gross margin headwind from weight loss and international mix.

Updated neutral analysis

• What the call resolved: the identity and status of the legal contingency (the FTC, contested), the itemization of the $81m of non-recurring costs, the Eucalyptus revenue contribution of approximately $40m, the organic international growth rate of 13% sequentially, the domestic revenue figure of $622m at 16% growth, and the direction of gross margin from here.
• What the call did not resolve: the prior full-year adjusted EBITDA range, so the size of the revision is still not stated by the company; the quantified split of the gross margin decline between acquisition mix, weight-loss shift and pricing; the potential size of any FTC outcome beyond the accrual already taken; the timing and cash-versus-share form of the deferred acquisition payable of $537.381m current and $165.624m long-term plus $162.964m of earn-out consideration flagged in the preliminary, which the call did not address; and whether the company's Q1 2026 definition change to adjusted EBITDA affects comparability with consensus.
• The two headline facts of this quarter now sit in clearer tension. Revenue beat consensus by 7.8% and full-year revenue guidance went up, while the GAAP result was a $(86)m net loss and the full-year adjusted EBITDA outlook appears to have gone down. The call attributes essentially all of that divergence to deliberate spending: AI, international, and a stated willingness to cut weight-loss prices, with the FTC accrual and Eucalyptus closing costs as the non-recurring overlay.
• The margin path to 2030 remains the longest-dated open item. An 8% adjusted EBITDA margin this quarter and roughly 9% guided for the year against a 2030 ambition implying about 20%, with management simultaneously guiding gross margins structurally lower and signalling price cuts, means the entire margin bridge has to come from operating leverage and AI cost savings. Management reaffirmed the 2030 numbers and described increased conviction but did not bridge them.
• Nothing on the call changed the consensus scorecard. Both rows are carried forward from the preliminary report unchanged.

Market context and limitations

• The transcript for Quartr event 666009 is complete and not live. All 90 paragraphs were read, covering the prepared remarks from the CEO, CTO and CFO, two retail-community questions, and the full analyst Q&A with Maria Ripps (Canaccord), Ryan MacDonald (Needham), Mark Mahaney (Evercore), Craig Hettenbach (Morgan Stanley), Eric Percher (Nephron Research) and Glen Santangelo (Barclays).
• API Ninjas price snapshot for HIMS returned $31.77 on NYSE with volume of 16,101,097. That price and volume are identical to the snapshot recorded in the preliminary report at 2026-08-10T20:52:54Z, before the call, so the provider is re-serving a stale quote and it carries no information about the post-call reaction. No market reaction to the call is characterized here.
• Every figure in the consensus scorecard is carried forward from the preliminary report for this event and was not recalculated. Figures attributed to management in this report come from the transcript, and figures attributed to the release come from the preliminary report, which sourced them from Quartr earnings release document 3688061.
• The $81m of non-recurring costs stated on the call and the $47.5m of legal contingencies plus $28.8m of acquisition costs stated in the release imply roughly $4.7m of restructuring cost. That figure is a local subtraction from two separately disclosed numbers, not a company disclosure, and the two sources may not be drawn on identical bases.
• Management's characterization of the full-year adjusted EBITDA guide as reduced is inferred from an analyst's unchallenged framing on the call. Neither the release nor the call states the prior range, so the revision is not quantified anywhere in the source material.
• The slide deck attached to this event (document 3997398) was not read for this update.